CHMP Issues Positive Opinion For Tablet Formulation Of Merck & Co., Inc.’s NOXAFIL® (posaconazole)

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of a new, investigational tablet formulation of NOXAFIL® (posaconazole).

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC